Carol Peña

3.5k total citations · 2 hit papers
9 papers, 2.3k citations indexed

About

Carol Peña is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Carol Peña has authored 9 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Carol Peña's work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Cancer Genomics and Diagnostics (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Carol Peña is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Cancer Genomics and Diagnostics (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Carol Peña collaborates with scholars based in France, United States and Germany. Carol Peña's co-authors include Furio Pacini, Ralf Paschke, Steven I. Sherman, Christelle de la Fouchardière, Christopher M. Nutting, Lars Bastholt, Barbara Jarząb, István Molnár, Martin Schlumberger and John Chung and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of Hepatology.

In The Last Decade

Carol Peña

9 papers receiving 2.3k citations

Hit Papers

Sorafenib in radioactive iodine-refractory, locally advan... 2009 2026 2014 2020 2014 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    2014 1.2k citations Marcia S. Brose, Christopher M. Nutting et al. The Lancet profile →
  2. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
    2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol Peña France 7 910 910 875 765 492 9 2.3k
Cristiana Lupi Italy 18 708 0.8× 1.2k 1.3× 631 0.7× 1.7k 2.2× 370 0.8× 35 2.8k
Shuanzeng Wei United States 20 908 1.0× 379 0.4× 1.0k 1.2× 504 0.7× 540 1.1× 73 2.1k
Jessica Read United Kingdom 9 428 0.5× 762 0.8× 514 0.6× 733 1.0× 165 0.3× 11 1.6k
Annetta Krebs United States 8 723 0.8× 411 0.5× 1.9k 2.1× 2.0k 2.6× 395 0.8× 8 2.8k
Elisa Sensi Italy 20 609 0.7× 424 0.5× 586 0.7× 1.5k 2.0× 396 0.8× 44 2.3k
Yu-Nien Sun United States 10 528 0.6× 527 0.6× 332 0.4× 566 0.7× 196 0.4× 12 1.4k
Michael T. Schweizer United States 33 929 1.0× 346 0.4× 2.2k 2.5× 1.1k 1.4× 746 1.5× 144 3.1k
Limin Hsu United States 15 840 0.9× 277 0.3× 269 0.3× 920 1.2× 608 1.2× 25 1.8k
Yifah Yaron United States 11 336 0.4× 632 0.7× 382 0.4× 615 0.8× 149 0.3× 17 1.4k
Suneel Mundle United States 28 913 1.0× 307 0.3× 1.5k 1.7× 560 0.7× 638 1.3× 131 3.3k

Countries citing papers authored by Carol Peña

Since Specialization
Citations

This map shows the geographic impact of Carol Peña's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Peña with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Peña more than expected).

Fields of papers citing papers by Carol Peña

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Peña. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Peña. The network helps show where Carol Peña may publish in the future.

Co-authorship network of co-authors of Carol Peña

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Peña. A scholar is included among the top collaborators of Carol Peña based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Peña. Carol Peña is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Marmé, Frederik, et al.. (2018). Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. Cancer Chemotherapy and Pharmacology. 81(4). 727–737. 3 indexed citations
2.
Morschhauser, Franck, Krimo Bouabdallah, Dominique Bron, et al.. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology. 28(9). 2169–2178. 192 indexed citations
3.
Lin, Shi-Ming, Sheng‐Nan Lu, Long‐Bin Jeng, et al.. (2016). HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Hepatology International. 11(2). 199–208. 14 indexed citations
4.
Paz‐Ares, Luis, Vera Hirsh, Li Zhang, et al.. (2015). Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial. Journal of Thoracic Oncology. 10(12). 1745–1753. 93 indexed citations
5.
Brose, Marcia S., Christopher M. Nutting, Barbara Jarząb, et al.. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 384(9940). 319–328. 1153 indexed citations breakdown →
6.
7.
Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →
8.
9.
Soria, Jean‐Charles, Vladimir Lazar, Nathalie Lassau, et al.. (2007). Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). Journal of Clinical Oncology. 25(18_suppl). 3556–3556. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristiana Lupi Breakdown of academic impact, for papers by Shuanzeng Wei Breakdown of academic impact, for papers by Jessica Read Breakdown of academic impact, for papers by Annetta Krebs Breakdown of academic impact, for papers by Elisa Sensi Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by Limin Hsu Breakdown of academic impact, for papers by Yifah Yaron Breakdown of academic impact, for papers by Suneel Mundle
Rankless by CCL
2026